Author:
Quintanilha Julia C. F.,Liu Yingmiao,Etheridge Amy S.,Yazdani Akram,Kindler Hedy L.,Kelly William Kevin,Nixon Andrew B.,Innocenti Federico
Funder
National Cancer Institute of the National Institutes of Health
Foundation for the National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Biochemistry,Physiology
Reference48 articles.
1. Garcia J, Hurwitz HI, Sandler AB et al (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017
2. EMA summary of product characteristics (2017). https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Accessed 05 Oct 2020
3. FDA AVASTIN®prescribing information (2020). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125085s332lbl.pdf. Accessed 05 Oct 2020
4. Quintanilha JCF, Wang J, Sibley AB et al (2020) Bevacizumab-induced hypertension and proteinuria: a genome-wide analysis of more than 1,000 patients. Eur J Cancer 138:S9–S10
5. Moslehi JJ (2016) Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375:1457–1467